Use of a glycosamine sulfate for patients with osteoarthritis and a comorbidity with high risk of the side effects from NSAIDS


Cite item

Full Text

Abstract

The literature review is devoted to the peculiarities of treating co-morbid patients with acute conditions of chronic pain. The proved effect of NSAIDS must always correlate with the side effect risk. Patented microcrystalline glucosamine sulfate (pCGS) is likely to have an effect similar to NSAIDS because it can cause decrease of COX-2 and PGE2 gene expression. Randomized trials show, that patented microcrystalline glucosamine sulfate can impede complex structure changes and have a positive effect on the symptoms at the early stage of knee OA. Pharmacokinetic evidence demonstrates that repeated oral intake of microcrystalline glucosamine sulfate can cause the increase of GS in synovial fluid. It is necessary to monitor OA biomarkers during microcrystalline GS treatment, recommend appropriate physical exercise and study the neuropathic component of chronic pain.

About the authors

A V Naumov

Habilitation degree in Medicine, Russian Scientific Clinical Centre of Gerontology; FSBEI of Higher Education "N.I.Pirogov National Medical University"

Email: nanton78@gmail.com
д.м.н., проф., каф. болезней старения, ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Минздрава РФ, обособленное структурное подразделение - Российский геронтологический научно-клинический центр Moscow, Russia

O N Tkacheva

Habilitation degree in Medicine, Russian Scientific Clinical Centre of Gerontology; FSBEI of Higher Education "N.I.Pirogov National Medical University"

проф., д.м.н., главный внештатный специалист гериатр Минздрава РФ, директор Российского геронтологического научного клинического центра Moscow, Russia

References

  1. Breivik H, Collett B, Ventafridda V et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006; (10): 287-333.
  2. Zhang W, Nuki G, Moskowitz R.W, Abramson S, Altman R.D, Arden N.K et al. OARSI recommendations for themanagement of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis and Cartilage/OARS, Osteoarthritis Research Society. 2010;18(4):476e99. Epub 2010/02/
  3. Mc Alindon T.E, Bannuru R.R, Sullivan M.C, Arden N.K, Berenbaum F, Bierma-Zeinstra S.M, Hawke G.A, Henrotin Y, Hunter D.J, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos E.M, Underwood M. OARSI guidelines for the non - surgical management of knee osteoarthritis. Osteoarthritis and Cartilage. 2014; 22: 363-388.
  4. Delitto A, George S.Z, Van Dillen L et al. Low Back Pain. Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability, and Health from the Orthopaedic Section of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2012; 42(4): 1-57.
  5. Goertz M, Thorson D, Bonsell J et al. Adult Acute and Subacute Low Back Pain. Health Care Guideline. Institute for Clinical Systems Improvement. Updated November. 2012; 92. www.icsi.org
  6. Алексеева Л.И., Наумов А.В. Ведение остеоартрита с коморбидностью в общей врачебной практике (Клинические рекомендации). Доктор.ру. 2017; 5 (134):51-69.
  7. De Munter W, Blom A.B, Helsen M.M, Walgreen B, Van der Kraan P.M, Joosten L. A.B, van den Berg W.B, Van Lent P.L. Cholesterol accumulation caused by low density lipoprotein receptor deficiency or a cholesterol - rich diet results in ectopic bone formation during experimental osteoarthritis. Arthritis Research & Therapy. 2013; 15: 178.
  8. Conaghan P.G, Vanharanta H, Dieppe P.A. Is progress - sive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis. 2005; 64: 1539-1541.
  9. De Vries H.E, Buchner B, Van Berkel T.J.C, Kuiper J. Specific interaction of oxidized low - density lipoprotein with macrophage - derived foam cells isolated from rabbit atherosclerotic lesions. Arterioscler Throm Vase Biol. 1999;19: 638-645.
  10. Findlay D.M. Review: Vascular pathology and osteoarthritis. J Rheumatol. 2007; 46: 1763-1768.
  11. Kadam U.T, Blagojevic M, Belcher J. Statin Use and Clinical Osteoarthritis in the General Population: A Longitudinal Study. J Gen Intern Med. 2013; 28(7): 943-949.
  12. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in the Elderly. Aging Dis. 2018; 9(1): 143-150.
  13. Harirforoosh S, Asghar W, Jamali F Advers effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013; 16: 821-847.
  14. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23.
  15. Верткин А.Л., Вовк Е.И., Наумов А.В., Шамуилова М.М., Иванов В.С., Филимонов В.С., Отпущенко А.В. Лечение и профилактика поражений слизистой оболочки желудочно - кишечного тракта в терапевтической практике. Клинические перспективы гастроэнтерологии, гепатологии. 2008; 5.
  16. Association of NSAID Use vith Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction. JAMA. 2015;313(8):805-814.
  17. Bruyère, Olivier et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism. Volume 44, Issue 3: 253-263.
  18. Rovati L.C, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012; 4:167-180.
  19. Reginster J.L, Bruyere O, Cooper C. Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis. 2017.
  20. Wandel S, Juni P, Tendal B et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta - analysis. BMJ. 2010; 341: 4675.
  21. Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheum. 2011; 2011: 969012. doi: 10.1155/2011/969012
  22. Gosset M, Berenbaum F, Levy A et al. Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a mechanosensitive gene. Arth Res Ther. 2006; 8(4):135.
  23. Gouze J.N, Bianchi A, Becuwe P et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Letters. 2002; 510(3):166-170.
  24. Largo R, Alvarez-Soria M.A, Diez-Ortego I et al. Glucosamine inhibits IL-1beta - induced NF-kappaB activation in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage. 2003; 11(4):290-298.
  25. Gouze J.N, Bordji K, Gulberti S et al. Interleukin-1beta down - regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta - mediated effects in rat chondrocytes. Arthritis & Rheumatism. 2001; 44(2):351-360.
  26. Shikhman A.R, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1 beta - mediated activation of human chondrocytes. J Immunol. 2001;166(8):5155-5160.
  27. Jang B.C, Sung S.H, Park J.G et al. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome - dependent manner. J Biol Chem. 2007;282(38):27622-27632.
  28. Chiusaroli R, Piepoli T, Zanelli T et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011:939265.
  29. Chan P.S, Caron J.P, Rosa G.J.M, Orth M.W. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E2 in articular cartilage explants. Osteo Arthritis and Cartilage. 2005; 13: 387-394.
  30. Calamia V, Ruiz-Romero C, Rocha B, Fernandez-Puente P, Mateos J, Montell E, Verges J, Blanco F.J. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010;12(4): 138.
  31. Largo R, Alvarez-Soria M.A, Díez-Ortego I, Calvo E, Sánchez-Pernaute O, Egido J, Herrero-Beaumont G. Glucosamine inhibits IL-1beta - induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003; 11(4):290-8.
  32. Ströhle A, Schneiders T. Nutritional medical aspects of osteoarthritis therapy. In: Jerosch J, Heisel J, editors. Management of Osteoarthritis. Köln, Germany: Deutscher Ärzte-Verlag. 2010; 41-57.
  33. Jos Runhaar, Rita Deroisy, Marienke van Middelkoop, Francesco Barretta, Beatrice Barbetta, Edwin H. Oei, Dammis Vroegindeweij, Giampaolo Giacovelli, Olivier Bruyère, Lucio C. Rovati, Jean-Yves Reginster, Sita M.A. Bierma-Zeinstra, The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. Seminars in Arthritis and Rheumatism. 2016; 45(4 Suppl): 42-48. ISSN 0049-0172
  34. Zhang W, Nuki G, Moskowitz R.W et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18:476-499.
  35. Bjordal J.M, Klovning A, Ljunggren A.E. Short - term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta - analysis of randomised placebo - controlled trials. Eur J Pain. 2007;11:125-138.
  36. de Vos B.C, Landsmeer M.L.A, van Middelkoop M. Long - term effects of a lifestyle intervention and oral glucosamine sulphate in primary care on incident knee OA in overweight women. Rheumatology (Oxford). 2017 Aug 1;56(8):1326-1334.
  37. Runhaar J, Rozendaal R, van Middelkoop M. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta - analysis from the OA trial bank. Ann Rheum Dis. 2017; 76(11):1862-1869.
  38. Peluso R, Caso F, Costa L. Mud - bath therapy and oral glucosamine sulfate in patients with knee osteoarthritis: a randomized, controlled, crossover study. Clin Exp Rheumatol. 2016; 34(4):618-24.
  39. Herrero-Beaumont G, Ivorra J.A, Del Carmen Trabado M et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double - blind, placebo - controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007; 56:555-567.
  40. Reginster J.Y, Deroisy R, Rovati L.C et al. Long - term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo - controlled clinical trial. Lancet. 2001; 357:251-256.
  41. Pavelka K, Gatterova J, Olejarova M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo - controlled, double - blind study. Arch Intern Med. 2002; 162:2113-2123.
  42. Caridad Pontes, Josep Ramon Marsal, Josep Maria Elorza, Maria Aragón, Daniel Prieto-Alhambra, Rosa Morros. Analgesic Use and Risk for Acute Coronary Events in Patients with Osteoarthritis: A Population - based, Nested Case - control Study. Clinical Therapeutics. 2018; 40(2): 270-283.
  43. Pocobelli G, Kristal A.R, Patterson R.E et al. Total mortality risk in relation to use of less - common dietary supplements. Am J Clin Nutr. 2010; 91: 1791-800.
  44. Katoh A, Kai H, Harada H, Niiyama H, Ikeda H. Oral Administration of Glucosamine Improves Vascular Endothelial Function by Modulating Intracellular Redox State. Int Heart J Ass. 2017;58 (6): 926-932.
  45. Цветкова Е.С., Денисов Л.Н. Симптоматическая терапия остеоартроза коленных суставов - новые возможности. Научно - практическая ревматология. 2011; 6.
  46. Цветкова Е.С, Иониченок Н.Г., Карусинов П.С., Олюнин Ю.А., Пушкова О.В., Смирнов А.В., Панасюк Е.Ю. Клинико - инструментальная оценка влияния фармакотерапии на течение остеоартроза коленных суставов. Научно - практическая ревматология. 2007; (1).
  47. Senin P, Makovec F, Rovati L. (1987) Stable compounds of glucosamine sulfate. USA Patent 4642340.
  48. Persiani S, Roda E, Rovati L.C, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005;13:1041-1049. doi: 10.1016/j.joca.2005.07.009
  49. Persiani S, Rotini R, Trisolino G, Rovati L.C, Locatelli M, Paganini D, Antonioli D, Roda A. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage. 2007;15:764-772. doi: 10.1016/j.joca.2007.01.019
  50. Setnikar I, Rovati L.C. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001;51:699-725.
  51. Persiani S, Matthews A, Larger P, Hall M, Rotini R, Trisolino G, Antonioli D, Zaccarelli L, Rovati L.C. Glucosamine binding to proteins in plasma and synovial fluid and blood cell/plasma partitioning in mouse and man in vitro. Drug Metabol Drug Interact. 2009;24:211-227. doi: 10.1515/DMDI.2009.24.2-4.211

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies